Announced details
Treatment of patients with esophageal cancer who are unable to undergo curative surgery or chemoradiotherapy
Sales partner. The product will be supplied to medical institutions by pharmaceutical wholesalers through Fujifilm Toyama Chemical Co., Ltd.
Ministry of Health, Labour and Welfare (the disclosure states that the permits required for sales have been obtained)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Telomelysin® Injection (generic name: suratadenoturev; development code: OBP-301) |
| Counterparty | FUJIFILM Toyama Chemical Co., Ltd. |
| Relationship with the Company | Sales partner. The product will be supplied to medical institutions by pharmaceutical wholesalers through Fujifilm Toyama Chemical Co., Ltd. |
| Launch date | 21 August 2026 (actual; sales launch date) |
| Applicable area | Treatment of patients with esophageal cancer who are unable to undergo curative surgery or chemoradiotherapy |
| Awarding / certifying body | Ministry of Health, Labour and Welfare (the disclosure states that the permits required for sales have been obtained) |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The product obtained standard approval in Japan on 8 June 2026 and was launched as a new treatment option for patients with esophageal cancer who are unable to undergo curative surgery or chemoradiotherapy.